Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Can drug-induced platelet dysfunction be reversed?

Suzanne Maynard1,2,3, Alexander P Bye4, Michael J R Desborough1,2,3

  • 1Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom.

Research and Practice in Thrombosis and Haemostasis
|January 16, 2026
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Fetal and neonatal alloimmune thrombocytopenia (FNAIT): Survey of UK fetal medicine centres on antenatal management of subsequent affected pregnancies.

British journal of haematology·2026
Same author

A Reply to "Beyond Implementation: The Need for Validation, Equity, and Real-World Accountability in AI for Transfusion Medicine".

Transfusion medicine reviews·2026
Same author

Artificial Intelligence Implementation in Transfusion Medicine: Addressing the Challenges of Clinical Adoption.

Transfusion medicine reviews·2026
Same author

Antiplatelet Resistance: A Review of Concepts, Mechanisms, and Implications for Management in Acute Ischemic Stroke and Transient Ischemic Attack.

Stroke (Hoboken, N.J.)·2026
Same author

Recombinant von Willebrand Factor (vonicog alfa) reduces platelet inhibition caused by antiplatelet drugs and has potential as an acute haemostatic agent.

Haematologica·2026
Same author

Improving transfusion access through improved policy: a call for a less fragmented blood supply.

Expert review of hematology·2025
Same journal

Heparin to prevent recurrent placenta-mediated pregnancy complications in women with antiphospholipid syndrome: a systematic review.

Research and practice in thrombosis and haemostasis·2026
Same journal

Thromboembolic ischemic stroke induces neutrophil recruitment and matrix metalloproteinase-9 release to enhance ischemic brain injury.

Research and practice in thrombosis and haemostasis·2026
Same journal

Real-world investigation of platelet apoptosis for mechanistic insights into severe immune thrombocytopenia and bleeding.

Research and practice in thrombosis and haemostasis·2026
Same journal

Antiphospholipid antibody formation during immune checkpoint inhibition in patients with cancer: a prospective cohort study.

Research and practice in thrombosis and haemostasis·2026
Same journal

Venous thromboembolic and bleeding risk in population with obesity hospitalized for an acute medical illness receiving enoxaparin for thromboprophylaxis.

Research and practice in thrombosis and haemostasis·2026
Same journal

Identifying risk factors for venous thromboembolism in medical inpatients: a systematic review and meta-analysis.

Research and practice in thrombosis and haemostasis·2026
See all related articles

Reversing antiplatelet drugs may reduce bleeding risks in patients with serious conditions. However, current reversal strategies like platelet transfusions and tranexamic acid have limitations, necessitating further research for effective treatments.

Area of Science:

  • Pharmacology
  • Hematology
  • Clinical Medicine

Background:

  • Antiplatelet drugs are crucial for arterial disease but increase bleeding risk.
  • Conditions like intracerebral hemorrhage have higher mortality in patients on antiplatelet therapy.
  • Reversal agents aim to mitigate bleeding but carry thrombotic risks.

Purpose of the Study:

  • To review current strategies for reversing antiplatelet drug effects.
  • To highlight the need for evidence-based efficacy of reversal agents.
  • To assess risks and benefits of available and emerging reversal options.

Main Methods:

  • Review of clinical trials and studies on antiplatelet reversal agents.
  • Analysis of outcomes including mortality, morbidity, and thrombotic complications.
Keywords:
antiplatelet drugsbentracimabdesmopressinplatelet transfusiontranexamic acid

Related Experiment Videos

  • Evaluation of agents such as platelet transfusion, tranexamic acid, desmopressin, and bentracimab.

    • Main Results:

    • Platelet transfusion showed increased risk in intracerebral hemorrhage.
    • Tranexamic acid's risks/benefits appear similar in patients with or without antiplatelet drugs.
    • Desmopressin showed promise but needs further study; bentracimab showed efficacy in a single-arm trial.

    Conclusions:

    • There is a significant unmet need for high-quality studies on antiplatelet reversal strategies.
    • Clinically relevant outcomes must guide the assessment of reversal agent efficacy.
    • Balancing reversal benefits against thrombotic risks remains a critical challenge.